Minimal HER1 and HER2 expressions in CHO and HEK-293 cells cause them appropriate negative cells for HERs-related studies

Background and aim: understanding of cellular and molecular mechanismsinvolved in cell/tumor growth and progression has led to molecular-targetedtherapy. her1 and her2 are two main oncogenic components of her-receptorfamily considered as targets for cancer research and therapy. reliable results ofher- related research and targeted therapies dependent upon cell line with knownher expression status. but there are no published studies focusing ondetermination of her1 and her2 receptors expression in cho and hek-293 celllines.methods: absolute expressions of her1 and her2 in cho, hek-293, mdamb-468 and skbr3 cells were evaluated using quantitative real-time pcr.absolute expression quantification was carried out by serial dilution plasmidsharboring her1 and her2 to extrapolate standard curve.results: real-time pcr amplification was successfully optimized by her1 andher2 plasmids with high efficiency and their copy numbers were calculated. theresults showed that her1 was not expressed in cho and hek-293 cells but thesecells express her2 up to 9.4 × 102 and 1.1 × 105 copy/?g, respectively. mdamb-468 and skbr3 cells express her1 up to 8.4 × 105 and 9.7 × 104,respectively. in addition, the expression of her2 is higher on the surface ofskbr3 cell (6.5 × 106 copy/?g).conclusion: our study provides a proven insight to her1 and her2 expressionstatus in cho, hek-293, mda-mb-468 and skbr3 cells. heterologousexpression of her1 and her2 in cell lines is the first step in structural andfunctional studies. since her1 is not expressed in cho and hek-293endogenously, these cells are ideal for her receptor related studies.